Cardiac Surgery

Bio-inspired glue keeps hearts securely sealed

When a child is born with a heart defect such as a hole in the heart, the highly invasive therapies are challenging due to an inability to quickly and safely secure devices inside the heart. Sutures take ...

Jan 08, 2014
popularity 4.7 / 5 (3) | comments 0

New drug may protect the heart during ischemia

Research from three Yale laboratories—in the fields of immunobiology, chemistry, and cardiology—could lead to new drugs to reduce complications during cardiac surgery or heart attacks. If they pan out in human trials, ...

Jul 24, 2013
popularity 5 / 5 (1) | comments 0

Cardiovascular surgery is surgery on the heart or great vessels performed by cardiac surgeons. Frequently, it is done to treat complications of ischemic heart disease (for example, coronary artery bypass grafting), correct congenital heart disease, or treat valvular heart disease from various causes including endocarditis, rheumatic heart disease and atherosclerosis. It also includes heart transplantation.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Popular antioxidant likely ineffective, study finds

The popular dietary supplement ubiquinone, also known as Coenzyme Q10, is widely believed to function as an antioxidant, protecting cells against damage from free radicals. But a new study by scientists at McGill University ...

Research suggests brain's melatonin may trigger sleep

If you walk into your local drug store and ask for a supplement to help you sleep, you might be directed to a bottle labeled "melatonin." The hormone supplement's use as a sleep aid is supported by anecdotal ...

New understanding of stroke damage may aid recovery

Stroke can lead to a wide range of problems such as depression and difficulty moving, speaking and paying attention. Scientists have thought these issues were caused by damage to the brain's "computer processors"—cells ...

FDA approves first lower-cost biotech drug (Update)

Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.